Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

Trial Profile

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Alectinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Anaplastic large cell lymphoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 13 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 27 Jun 2018 Planned initiation date changed from 18 Jun 2018 to 26 Sep 2018.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top